Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iberdomide - Bristol Myers Squibb

Drug Profile

Iberdomide - Bristol Myers Squibb

Alternative Names: BMS-986382; CC-220; IBER; Iberdomide hydrochloride

Latest Information Update: 25 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Bristol-Myers Squibb; Celgene Corporation; Hackensack Meridian Health
  • Class Anti-inflammatories; Antineoplastics; Isoindoles; Piperidones; Skin disorder therapies; Small molecules
  • Mechanism of Action Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase II Atopic dermatitis; Systemic lupus erythematosus
  • Phase I B-cell lymphoma; Follicular lymphoma; Renal failure
  • No development reported Non-Hodgkin's lymphoma
  • Discontinued Cutaneous lupus erythematosus; Haematological malignancies; Sarcoidosis; Systemic scleroderma

Most Recent Events

  • 05 Apr 2024 Phase-III clinical trials in Multiple myeloma (Combination therapy, First-line therapy) in Germany (PO) (NCT06216158)
  • 12 Mar 2024 Hackensack Meridian Health suspends a Phase-I/II clinical trials in Multiple myeloma (Combination therapy, First-line therapy) in USA (PO) due to serious adverse event which is under review (NCT05199311)
  • 20 Feb 2024 Pfizer initiates the phase I MagnetisMM-4 trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Canada (PO) (NCT06215118)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top